Several million patients in Germany are treated with statins. In 2004, the consumption of lipid-lowering drugs throughout Germany amounted to around 856 million defined daily doses (DDD). In 2011 the amount increased to: 1.718 million DDD. With the target to lower cholesterol levels, this doubtful strategy is still being mistakenly promoted to reduce heart disease risk. As a side effect, doctors and patients are accepting a possible cognitive decline. These are the results of a study published in 2018 in the journal Frontiers in Neurology, which looked into the relationship between cholesterol and cognitive function . While cholesterol is still largely vilified, and statin use still heavily promoted, the study found that having lower levels of low-density lipoprotein (LDL) cholesterol is linked to a higher risk of dementia.
The focus of Alzheimer’s research has been, so far, the molecular process which leads to a change in the brain structure, above all and first in the hippocampus. Here, an increased formation of amyloid beta (Aß) plaques is observed in the brains of Alzheimer patients. These protein adhesions impair the communication between nerve cells. Such alterations are attributed to ageing and genetic predisposition. As a result, Alzheimer’s research has been searching for years (but without any success) for a drug therapy to eliminate or at least reduce plaque formation. A very monocausal view of the problem.